Healthcare providers commonly use obstetric ultrasound to assess fetal well-being. However, the potential for fetal findings to manifest maternal disease is often underappreciated. This article will review the relationships between obstetric ultrasound findings and underlying maternal medical conditions in three settings: (1) fetal growth abnormalities related to underlying maternal disease, (2) congenital malformations secondary to diabetes and maternal exposure to chemical and infectious teratogens, and (3) congenital heart block due to maternal autoimmune disease. The obstetric ultrasound should be a tool used for the care and evaluation of the maternal as well as the fetal patient.
INTRODUCTION
Ultrasound is a useful tool in caring for the complex maternal medical patient. Often the ultrasound tells about fetal health but it can also be a window into maternal health.
Fetal Growth Abnormalities
Fetal growth abnormalities on either end of the spec trum may be a manifestation of maternal disease. Therefore, while maternal disease warrants ultrasound screening for fetal growth abnormalities, conversely, fetal growth abnormalities should trigger consideration for undiagnosed maternal disease. Maternal medical conditions associated with fetal growth restriction include pregestational diabetes, renal insufficiency, autoimmune
10.5005/jp-journals-10009-1440
disease, cyanotic cardiac disease, hypertension, and substance use (e.g. tobacco, narcotics and cocaine). 1 Fetal growth restriction secondary to teratogenic maternal medications is another way in which growth abnor malities may be manifestation of maternal health.
There is no universal consensus on the definition of fetal growth restriction. The American College of Obstetricians and Gynecologists considers fetal growth restriction to be estimated fetal weight less than the 10th percentile for gestational age. 2 However, the prospective observational trial to optimize pediatric health in intrauterine growth restriction (IUGR) (PORTO) study found that adverse outcomes were not consistently associated with fetal growth restriction until the estimated fetal weight dropped below the 3rd percentile. 3 Excessive fetal growth may be described as large for gestational age (birthweight > 90th percentile for gestational age) or macrosomia (fetal weight exceeding 4000 or 4500 gm). 4, 5 In addition to pregestational and gestational diabetes, maternal gestational weight gain and obesity are also risk factors for macrosomia.
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Fetal growth abnormalities are also predictive of future maternal health. 6, 9, 10 Increased mortality from coronary heart disease has been associated with mothers with a history of either low or high birthweight neonates compared to the reference offspring weighing 2500 to 3999 gm. 1 The association persists after adjustment for preeclampsia, diabetes, and socioeconomic factors. 6, 10 Genotypes linked to both abnormal fetal growth and cardiac mortality may be involved. Pathologic systemic maternal inflammation leading to poor uteroplacental perfusion is another possible etiology of both fetal growth restriction and future maternal disease. 11 Another potential mechanism is that women with marginal cardiac reserve may be unable to hemodynamically compensate for placental pathology, such as deficient placental growth factor and angiogenesis. 9 Thus, the resultant fetal underperfusion and growth restriction may be a symptom of otherwise subclinical maternal cardiac disease. Similarly, women with subclinical insulin resistance may be more prone to excessive fetal growth as well as metabolic disease later in life.
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Embryopathies
Major congenital malformations are found in approxi mately 3 to 4% of livebirths. 12 Nearly half of congenital malformations are of unknown etiology, and a large pro portion of the remaining cases are multifactorial or attributable to genetic abnormalities. However, approximately 4 to 6% of malformations in fetuses over 20 weeks gestational age are secondary to teratogenic expo sure, 3 and it is in these cases that maternal health may be a factor. It is estimated that 60 million reproductive age women worldwide are affected by diabetes mellitus, 13 and rates of maternal pregestational diabetes are increasing.
14 Pregestational diabetes is associated with a malformation rate approaching 9 to 10%. 15, 16 Multiple malformations are also increased in this population. 15, 17 Women with gestational diabetes may have a slightly higher risk of congenital malformations as well. 18 Malformations associated with pregestational diabetes are listed in Table 1 .
The risk for congenital malformations in diabetes is related to the degree of maternal hyperglycemia. SchaeferGraf et al found initial fasting glucose levels of 166 mg/dl in pregnancies affected by major anomalies in multiple organ systems, 141 mg/dl if one organ system was affected, and 115 mg/dl without major anomalies. 18 First trimester hemoglobin A1c values exceeding 9 to 10% have also been shown to predict malformations. 16, 19 It is hypothesized that at a cellular level maternal diabetes may increase oxidative and nitrosative stresses that lead to abnormal cell signaling, gene dysregulation, and apoptosis. 13 Polyhydramnios is another common ultrasound finding in pregnancies complicated by maternal diabetes, and diabetes is associated with up to 25% of cases of polyhydramnios. 20 Definitions of polyhydramnios vary, but the most commonly used criteria are a maximum vertical pocket > 8 cm or amniotic fluid index > 24 cm. The mechanism behind polyhydramnios and diabetes is thought to involve fetal hyperglycemia that leads to an osmotic diuresis with fetal polyuria. Another potential Teratogens are another means through which mater nal health impacts ultrasonographic fetal findings. A multi national study found that over 80% of women reported using at least one medication during pregnancy. Seventeen percent of women used medication for chronic medical conditions. 23 Some teratogenic medications pres cribed for chronic maternal disease include angiotensin converting enzyme inhibitors, lithium, warfarin, and carbamazepine. Ultrasound findings for selected medi cations are described in Table 2 . Alcohol abuse and dependence is another maternal condition that may manifest on obstetric ultrasound. Maternal alcohol use is the leading preventable cause of birth defects and developmental disabilities, and based on selfreport, 7.6% of pregnant women use alcohol. 24 While the findings of fetal alcohol syndrome exhibit a doseresponse relationship, there is no known safe lower limit for alcohol consumption during pregnancy. Fetal alcohol syndrome findings have been noted in patients consuming less than one drink per day and in all trimesters of exposure. 25 While there are no standard criteria for the prenatal diagnosis of fetal alcohol syndrome, prenatal ultrasound findings may include microcephaly, hypertelorism, cardiac anomalies (e.g. atrial and ventricular septal defects), renal anomalies, micrognathia, and a single umbilical artery. Fetal growth restriction, if present, is often early onset and symmetrical. 26 Other findings, such as frontal lobe/transcerebellar ratio, cavalcalvarial distance, frontothalamic measurements, and orbital diameter have been evaluated as potential markers for this condition. 27 Maternal infection with vertical transmission to the fetus is another etiology of congenital malformations. Findings from a selection of these infections are described in Table 3 . Cytomegalovirus is the most common congenital infection, affecting up to 2.2% of neonates. The risk of fetal transmission with primary maternal infection is 30 to 40% with the greatest risk in the third trimester of pregnancy. Amniotic fluid sampling can detect cytomegalovirus by culture or polymerase chain reaction (PCR), with sensitivities of 70 to 80% and 78 to 98% respectively.
DSJUOG
Fetal transmission in maternal parvovirus infection approximates 17 to 33%. The most severe effects generally occur with infection prior to 20 weeks gestation. Maternal serologic screening should be performed after possible exposure and amniotic fluid PCR can confirm the diagnosis with high sensitivity. If acute infection is diagnosed by either serologies or amniotic fluid PCR, ultrasounds every 1 to 2 weeks for 8 to 12 weeks after expo sure to monitor for fetal anemia.
Maternal varicella zoster infection may cause con genital varicella syndrome in 0.4 to 2% of preg nancies, primarily when infection occurs in the first or second trimesters. Maternal infection is often clinically diagnosed, though fluid from the vesicular lesions can be evaluated by PCR to confirm the diagnosis.
Toxoplasmosis is a parasite that can be contracted from undercooked meat or contact with infected cats or soil. Like cytomegalovirus, vertical transmission can occur in all trimesters, but is most likely to occur in the third trimester. Serologies are often inaccurate, and laboratories specialized in the performance of these tests are recommended for suspected infection. Polymerase chain reaction of the amniotic fluid has relatively high sensitivity and specificity.
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Congenital Heart Block
Congenital heart block affects 1 in 20,000 live births. 29 Half are associated with congenital cardiac malformations, such as left atrial isomerism or congenitally corrected transposition of the great arteries. 30 The other half of cases of congenital heart block are attributed to antiRo/SSA and antiLa/SSB antibodies in the setting of maternal autoimmune disease, generally Sjogren syndrome or systemic lupus erythematosus (SLE). 31 Conversely, having antiRo/SSA or antiLa/ SSB without a prior affected fetus carries a 2% risk of developing fetal heart block. 22, 32, 33 However, in the setting of a prior affected pregnancy the recurrence rate reaches 15 to 18%. 29, 34 It is believed that the antibodies bind to these antigens in the fetal myocardium, resulting in inflammation and fibrosis of the myocardium and conduction system, particularly the atrioventricular (AV) node. 35 Heart block is described as 1st, 2nd, or 3rd degree with increasing order of severity. First degree heart block manifests as a prolonged PR interval (> 150 ms). Second degree heart block is subclassified into type I (aka Wenckebach heart block) in which a progressively prolonged PR interval precedes a blocked P wave, and type II in which blocked P waves are not preceded by PR prolongation (Fig. 2) . Third degree heart block is characterized by completely independent atrial and ventricular contractions in the absence of any conduction through the AV node. While rare, other conduction abnormalities that have been reported in association with antiSSA/Ro antibodies include prolonged corrected QT interval, sinus bradycardia, cardiomyopathy, and endocardial fibroelastosis.
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Pregnancies complicated by antiSSA/Ro and/or anti SSB/La antibodies warrant an initial cardiac evaluation at 16 to 18 weeks for fetal heart block. While some suggest serial echocardiograms every 1 to 2 weeks starting from 16 to 18 weeks gestation to evaluate for the development of heart block, 22, 29 there are no formal guidelines on in utero monitoring. Congenital heart block may be the first manifestation of maternal autoimmune disease. Thus, this finding in a previously undiagnosed patient should prompt an evaluation of antiRo/SSA and antiLa/SSB antibodies. Patients with SLE and Sjogren syndrome in pregnancy require careful ultrasound surveillance through their antepartum course. In addition to the above mentioned cardiac evaluation in the presence of antiSSA/Ro and/ or antiSSB/La antibodies, first trimester ultrasound is recommended to confirm fetal viability as these patients are at increased risk for spontaneous abortion. In the third trimester, serial ultrasound evaluation for growth and amniotic fluid is indicated.
